Skip to main content
    C

    CryoCell International Inc (CCEL)

    Official site

    HEALTHCARE • MEDICAL CARE FACILITIES • AMEX

    $4.62
    +0.07 (+1.54%)

    Market Cap: $36.69M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    CryoCell International Inc (CCEL) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    CryoCell International (CCEL) has a market cap of $36.69M and an enterprise value of $44.37M. It earned -$1.95M on revenue of $31.13M over the last 12 months.

    Total Valuation

    Enterprise value is 20.96% above the market cap, as debt exceeds cash.

    Market Cap$36.69M
    Enterprise Value$44.37M
    Latest price (Nov 17, 2026)$4.62

    Key Dates

    The next earnings report is expected on Feb 25, 2027, covering the quarter ending Nov 30, 2026.

    Next Earnings DateFeb 25, 2027 (expected)
    Last Earnings DateOct 9, 2026
    Fiscal Year EndNovember

    Share Statistics

    The share count rose 0.09% in the quarter ended Aug 31, 2026 and held steady over 2 years.

    Shares Outstanding8.06M
    Shares Change (YoY)+0.06%
    Shares Change (QoQ)+0.09%
    Share Count Growth (2Y CAGR)0.00%

    Valuation Ratios

    The price to sales ratio is 1.2x. Its year-end P/S ranged from 0.9x to 3.2x from 2016 to 2025.

    Forward P/E56.6x
    P/S Ratio1.2x
    Forward P/S1.2x
    P/FCF Ratio8.0x
    P/OCF Ratio7.5x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 34.9x EBITDA and 9.7x free cash flow.

    EV / Sales1.4x
    EV / EBITDA34.9x
    EV / FCF9.7x

    Price Statistics

    The stock is up 12.41% over 52 weeks and trades 3.13% above its 50-day average.

    Beta (1Y)0.56
    52-Week Change+12.41%
    1-Month Change-0.65%
    3-Month Change+13.51%
    6-Month Change+31.62%
    5-Year Change-58.49%
    10-Year Change+27.07%
    Total Return (1Y)+12.41%
    Total Return (3Y CAGR)+5.01%
    Total Return (5Y CAGR)-14.38%
    Return vs SPY (1Y)+1.68%
    Max Drawdown (1Y)-35.00%
    Max Drawdown (3Y)-66.25%
    Sharpe Ratio (1Y)0.16
    Correlation with SPY (1Y)0.10
    50-Day Average$4.48
    200-Day Average$3.77
    52-Week Range$2.72 to $5.45
    RSI (14 Days)47.0
    Average Volume (20 Days)9.92K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.86x current liabilities.

    Current Ratio0.86x
    Quick Ratio0.82x
    Debt / EBITDA7.09x
    Debt / FCF1.96x
    Interest Coverage2.50x

    Returns and Efficiency

    Return on invested capital is 1.15% over the last 12 months, against a 5-year average of 351.04%.

    Return on Assets (ROA)-3.12%
    Return on Invested Capital (ROIC)1.15%
    Return on Capital Employed (ROCE)-0.18%
    ROA (5Y Average)-2.23%
    ROIC (5Y Average)351.04%
    Asset Turnover0.50x
    Inventory Turnover15.84x
    Receivables Turnover4.53x
    Cash Conversion Cycle-40 days

    Scores

    CCEL has an Altman Z-Score of -0.08, in the distress zone below 1.81, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score-0.08
    Altman Z ZoneDistress
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $31.13M over the last 12 months is down 1.96% from the 12 months before.

    Revenue$31.13M
    Revenue Growth (YoY)-1.96%
    Gross Profit$24.45M
    Operating Income$189.42K
    Pretax Income-$1.91M
    Net Income-$1.95M
    EBITDA$1.29M
    EBIT-$83.55K
    Reported EPS (TTM)-$0.22

    Trailing 12 months through Aug 31, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$1.43M
    Total Debt$9.11M
    Net Debt$7.69M
    Net Debt Per Share$0.95
    Working Capital-$2.16M
    Shareholder Equity-$16.39M
    Tangible Book Value-$19.17M
    Total Assets$62.30M
    Total Liabilities$78.70M

    Balance sheet as of Aug 31, 2026.

    Full balance sheet

    Cash Flow

    After $268.87K of capital spending, operating cash flow left $4.65M of free cash flow.

    Operating Cash Flow$4.92M
    Capital Expenditures$268.87K
    Free Cash Flow$4.65M
    FCF Per Share$0.58
    Depreciation and Amortization$1.37M

    Trailing 12 months through Aug 31, 2026.

    Full cash flow statement

    Margins

    The operating margin is 0.61%, against a 5-year average of 0.07%.

    Gross Margin78.54%
    Operating Margin0.61%
    Pretax Margin-6.13%
    Net Margin-6.25%
    EBITDA Margin4.13%
    EBIT Margin-0.27%
    FCF Margin14.94%
    Gross Margin (5Y Average)72.98%
    Operating Margin (5Y Average)0.07%
    Net Margin (5Y Average)-4.09%

    Growth

    Revenue grew 1.33% a year over 3 years.

    Revenue Growth (3Y CAGR)+1.33%
    Revenue Growth (5Y CAGR)+0.27%
    FCF Growth (5Y CAGR)-8.91%
    Operating Income Growth (3Y CAGR)-50.69%

    Revenue and profit by year

    Dividends and Yields

    CCEL does not pay a dividend. Its free cash flow yield is 12.49%.

    FCF Yield12.49%
    Shareholder Yield0.00%

    Peer Position

    Against 5 similar companies, CCEL has the 5th highest P/S.

    P/S Ratio1.2x vs 83.5x median
    ROIC1.15% vs -63.93% median
    Revenue Growth (Trailing 4 Quarters, YoY)-1.96% vs -55.27% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About CCEL

    What is CCEL's market cap?

    CryoCell International has a market cap of $36.69M. Its enterprise value, which adds debt and subtracts cash, is $44.37M.

    How many shares of CCEL are outstanding?

    CryoCell International has 8.06M shares outstanding. The count is up 0.06% from a year earlier.

    Does CCEL pay a dividend?

    No. CryoCell International does not pay a dividend.

    How much debt does CCEL have?

    CryoCell International has $9.11M of total debt and $1.43M of cash and equivalents, a net debt position of $7.69M.